Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Publication

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Journal Paper/Review - May 4, 2023

Chatziioannou Eftychia, Leiter Ulrike, Thomas Ioannis, Keim Ulrike, Seeber Olivia, Meiwes Andreas, Boessenecker Isabell, Gonzalez Stephanie Sanchez, Torres Francisco Merraz, Niessner Heike, Sinnberg Tobias, Forschner Andrea, Flatz Lukas, Amaral Teresa

Citation

Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez S, Torres F, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Am J Clin Dermatol 2023; 24:453-467.

Type

Journal Paper/Review (English)

Journal

Am J Clin Dermatol 2023; 24

Publication Date

May 4, 2023

Issn Electronic

1179-1888

Pages

453-467

Brief description/objective

Immune checkpoint inhibition (ICI) has changed the melanoma treatment spectrum. Few studies have examined the characteristics and long-term outcomes of patients achieving complete response (CR) under ICI.